Results of sizes reduction of patients with tuberous sclerosis complex-associated renal angiomyolipoma (TSC-AML) treated with everolimus for 2 years, n=11
| Patients | Group | Size (cm3) | RR (%) | Long-term PR (months) | Side effect | |
| Before | After | |||||
| 1 | I | 84.5 | 51.6 | 38.9 | − | Acne |
| 2 | I | 2.3 | 1.2 | 47.8 | − | Oral ulcers/acne |
| 3 | I | 2.0 | 1.4 | 30.0 | + (24) | Oral ulcers/cellulitis |
| 4 | I | 367.7 | 328.9 | 10.6 | − | Hyperlipidemia |
| 5 | I | 79.1 | 27.5 | 65.2 | + (6) | Oral ulcer |
| 6 | II | 2497.0 | 793.6 | 68.2 | + (12) | Oral ulcers |
| 7 | II | 94.8 | 35.2 | 62.9 | + (12) | Diarrhea |
| 8 | II | 544.5 | 159.9 | 70.6 | + (24) | Oral ulcers |
| 9 | II | 2473.7 | 1421.9 | 42.5 | + (60) | Oral ulcers, hyperlipidemia/DM/HTN |
| 10 | I | 77.2 | 45.7 | 40.8 | + (24) | Oral ulcer, hyperlipidemia, amenorrhea, proteinuria |
| 11 | II | 66.1 | 31.5 | 52.3 | + (6) | Oral ulcer, acne, hyperlipidemia, hyperglycemia amenorrhea, liver function impairment |
Mean trough level (μg/kg)<8: group I;>8: group II.
DM, diabetics mellitus; HTN, hypertension.; PR, partial response; RR, reduction rate.